EMEA-002572-PIP02-19-M03

EMEA-002472-PIP03-22-M01

Opinion/decision on a Paediatric investigation plan (PIP): Mounjaro, Tirzepatide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0285/2023

Opinion/decision on a Paediatric investigation plan (PIP): Ayvakyt, Avapritinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0281/2023

Opinion/decision on a Paediatric investigation plan (PIP): Prevenar 20 (previously Apexxnar), Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vaccines, PIP number: P/0246/2023

Opinion/decision on a Paediatric investigation plan (PIP): Camzyos, Mavacamten, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Cardiovascular diseases, PIP number: P/0278/2023

Opinion/decision on a Paediatric investigation plan (PIP): Xospata, Gilteritinib (as fumarate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology, PIP number: P/0267/2023

EMEA-001821-PIP01-15-M07

EMEA-001624-PIP01-14-M06

Opinion/decision on a Paediatric investigation plan (PIP): Natpar, Recombinant parathyroid hormone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0276/2023